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Sexually transmitted infections are important, but the 
diseases are easily neglected in daily clinical practice. 
Outcomes are heavily influenced by timely and accurate 
diagnoses as well as appropriate antimicrobial therapy. 
A series of symposia was held over the last year in order 
to develop suitable guidelines. Participants included ex-
perts in the fields of infectious diseases, urologist, AIDS 
caregiver, and the obstetrics and gynecology doctors. 
A consensus conference for establishing guidelines for 
treatment of sexually transmitted diseases in Taiwan was 
held on March 14, 2009 following a symposium on sexu-
ally transmitted infections held in conjunction with the 
Infections Diseases Society of Taiwan, Taiwan AIDS soci-
ety, Taiwan Urological Association, Taiwan Association of 
Obstetrics and Gynecology, the Medical Foundation in 
Memory of Dr Deh-Lin Cheng, Foundation of Professor 
Wei-Chuan Hsieh for Infectious Diseases Research and 
Education, and CY Lee’s Research Foundation for 
Pediatric Infectious Diseases and Vaccines. Many recom-
mendations are still based on expert opinions, sexually 
transmitted diseases guideline abroad and unpublished 
data, due to a paucity of well-designed, randomized, 
controlled clinical trials in this region. The choice of 
treatment regimens were based on opinions of primary 
care physicians and availability of drugs in Taiwan. Single 
dosing regimen was considered first. The treatment 
regimens on pelvic inflammatory disease were not in-
cluded because of a paucity of consensus. These guide-
lines are approved by the board of the Infectious Diseases 
Society of Taiwan, and a copy will be sent to physicians 
in all hospitals in Taiwan. These guidelines are published 
in the Journal of Microbiology, Immunology and Infection, 
and are also available at the Journal’s website (www.
e-jmii.com)
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